Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Running, not enrolling · Phase 3

Conditions studied: Multiple Myeloma

In brief

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Key facts

Study ID

NCT04975997

Run by

Celgene

People needed

939

Starts

2022-06-23

Expected to finish

2032-06-25

Last updated by the study team

2026-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of multiple myeloma (MM) and measurable disease.
• Received 1 to 2 prior lines of anti-myeloma therapy.
• Must have documented disease progression during or after their last anti-myeloma regimen.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.

You may not qualify if…

• Any condition that confounds the ability to interpret data from the study.
• Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
• Known central nervous system involvement with MM.
• Prior therapy with iberdomide.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Local Institution - 641 — Cerritos, California, United States
• Local Institution - 681 — Fountain Valley, California, United States
• Local Institution - 047 — Los Angeles, California, United States
• Local Institution - 684 — Newport, California, United States
• Local Institution - 033 — New Haven, Connecticut, United States
• Local Institution - 029 — Fort Myers, Florida, United States
• Local Institution - 693 — Ocala, Florida, United States
• Local Institution - 028 — St. Petersburg, Florida, United States
• Local Institution - 045 — Tamarac, Florida, United States
• Local Institution - 034 — West Palm Beach, Florida, United States
• Local Institution - 685 — Weston, Florida, United States
• Local Institution - 018 — Atlanta, Georgia, United States
• Local Institution - 640 — Elk Grove Village, Illinois, United States
• Local Institution - 697 — Dyer, Indiana, United States
• Local Institution - 040 — Louisville, Kentucky, United States
• Local Institution - 041 — Alexandria, Louisiana, United States
• Local Institution - 682 — Baton Rouge, Louisiana, United States
• Local Institution - 027 — Baton Rouge, Louisiana, United States
• Local Institution - 698 — Baltimore, Maryland, United States
• Local Institution - 014 — Bethesda, Maryland, United States
• Local Institution - 688 — Columbia, Maryland, United States
• Local Institution - 010 — Boston, Massachusetts, United States
• Local Institution - 009 — Worcester, Massachusetts, United States
• Local Institution - 645 — Burnsville, Minnesota, United States
• Local Institution - 035 — Hot Springs, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.